Given the significant immunomodulatory properties of KRAS G12C inhibitors, which can reshape the immune system and bolster anti-tumor responses, anti-PD-(L)1 therapies may achieve a synergistic effect when combined with KRAS G12C inhibitors. Here, KRAS is linked to neoplasm.